2.90
+0.11(+3.94%)
Currency In USD
| Previous Close | 2.79 |
| Open | 2.76 |
| Day High | 3.05 |
| Day Low | 2.73 |
| 52-Week High | 9.8 |
| 52-Week Low | 2.56 |
| Volume | 2.32M |
| Average Volume | 1.75M |
| Market Cap | 380.37M |
| PE | -1.41 |
| EPS | -2.06 |
| Moving Average 50 Days | 3.6 |
| Moving Average 200 Days | 5 |
| Change | 0.11 |
If you invested $1000 in Prime Medicine, Inc. (PRME) since IPO date, it would be worth $188.68 as of December 21, 2024 at a share price of $2.9. Whereas If you bought $1000 worth of Prime Medicine, Inc. (PRME) shares 1 year ago, it would be worth $331.05 as of December 21, 2024 at a share price of $2.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Prime Medicine to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 06, 2024 9:00 PM GMT
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
GlobeNewswire Inc.
Oct 24, 2024 12:00 PM GMT
Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies On track to initiate IND-enabling activities for Wilson
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
GlobeNewswire Inc.
Oct 15, 2024 12:00 PM GMT
-- On-track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company